Huntington's disease is a hereditary disorder caused by a genetic mutation in the HTT gene, leading to progressive brain cell ...

Scientists at the Broad Institute of MIT and Harvard, Harvard Medical School, and McLean Hospital have discovered a ...

New research shows that the mutation is, surprisingly, harmless for decades. But it quietly grows into a larger mutation — ...

To date clinical studies often show a poor B cell-mediated antibody response after an infection or vaccination in those with ...

Scientists have discovered a surprising mechanism by which the inherited genetic mutation known to cause Huntington's disease leads to the death of brain cells. The findings change the understanding ...

Sickled cells can obstruct the tiny blood vessels in the retina, the light-sensitive tissue at the back of the eye. This blockage reduces oxygen supply (ischaemia) and can result in retinal damage or ...

A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated ...